Showing 6921-6930 of 18626 results for "".
SunRISe-1: 1-Year Durability and Patient-Reported Outcomes Results
https://reachmd.com/clinical-practice/oncology-hematology/sunrise-1-1-year-durability-and-patient-reported-outcomes-results/33075/Dr. Neal Shore discusses new data presented at AUA 2025 from SunRISe-1 on TAR-200 monotherapy in patients with BCG-unresponsive high-risk NMIBC CIS.Considering the Promise of New and Emerging Treatments for Hemophilia: Managing Thrombotic Risks
https://reachmd.com/programs/cme/considering-the-promise-of-new-and-emerging-treatments-for-hemophilia-managing-thrombotic-risks/35552/Don’t miss this opportunity to learn the latest in new and emerging hemophilia therapies and optimize your patient care strategies.Moving Forward–What Is on the Horizon? Personalized Therapies for Patients
https://reachmd.com/programs/cme/moving-forwardwhat-is-on-the-horizon-personalized-therapies-for-patients/35555/Don’t miss this opportunity to learn the latest in new and emerging hemophilia therapies and optimize your patient care strategies.Postbiotics and Microneedling: An Emerging Approach for Acne Relief
https://reachmd.com/programs/clinicians-roundtable/postbiotics-and-microneedling-an-emerging-approach-for-acne-relief/30053/A recent study found that combining probiotics and microneedling shows potential as an alternative acne treatment. Read more about the results.Optimizing the Care and Quality of Life for Patients with ADPKD – Part 1: Detection and Diagnosis
https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12677/What are effective strategies for detecting and diagnosing patients who are at risk of autosomal dominant polycystic kidney disease?Bridging the Gap in AYA Cure Rates
https://reachmd.com/programs/medical-industry-feature/bridging-the-gap-in-aya-cure-rates/35630/Explore the latest data on asparaginase-based therapies for adolescents and young adults with acute lymphoblastic leukemia and lymphoblastic lymphoma. For US HCPs Only.Practical Perspectives in Myasthenia Gravis #3: Therapeutic Selection and Monitoring Efficacy—Matching Mechanisms to Patients
https://reachmd.com/programs/cme/mg-therapeutic-selection-and-monitoring-efficacy-matching-mechanisms-to-patients/39030/Examine evolving gMG management, from standard therapies to targeted agents, with an emphasis on pediatric care and assessment of treatment response.Valbenazine for TD: Consistent Long-Term Efficacy Across Racial and Ethnic Subgroups in KINECT-4
https://reachmd.com/clinical-practice/psychiatry-and-mental-health/valbenazine-for-td-consistent-long-term-efficacy-across-racial-and-ethnic-subgroups-in-kinect-4/37642/Valbenazine for TD: Consistent Long-Term Efficacy Across Racial and Ethnic Subgroups in KINECT-4What Challenges and Triumphs Do Patients Face While Living With PAH?
https://reachmd.com/programs/cme/what-challenges-and-triumphs-do-patients-face-while-living-with-pah/33242/Learn about applying patient-centered approaches in the management of pulmonary arterial hypertension (PAH) to optimize patient outcomes.The Latest Patient-Centered Recommendations From the 7th World Symposium on PH
https://reachmd.com/programs/cme/the-latest-patient-centered-recommendations-from-the-7th-world-symposium-on-ph/33236/Learn about applying patient-centered approaches in the management of pulmonary arterial hypertension (PAH) to optimize patient outcomes.